公开(公告)号：US20240229029A9

公开(公告)日：2024-07-11

申请号：US18471280

申请日：2023-09-20

Applicant: The Board of Regents of The University of Texas System

Inventor： David COREY ,  Liande LI

IPC: C12N15/113 ,  A61K45/06 ,  A61P25/00

CPC classification number: C12N15/113 ,  A61K45/06 ,  A61P25/00 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/3231

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

公开(公告)号：US20240200139A1

公开(公告)日：2024-06-20

申请号：US18547830

申请日：2022-02-25

Applicant: UNM Rainforest Innovations ,  The Board of Regents of the University of Texas System

Inventor： Nikolaos Mellios ,  Madhukar H. Trivedi

IPC: C12Q1/6883

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: A plurality of circular RNAs (circRNAs) the expression of which is correlated with diagnosis for Major Depressive Disorder (MDD) and Bipolar Disorder (BD) and response to treatment with various antidepressants is provided. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment, and/or monitoring of brain disorders such as MDD and BD.

公开(公告)号：US20240191254A1

公开(公告)日：2024-06-13

申请号：US18411647

申请日：2024-01-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Steven J. GRAY ,  Sarah SINNETT

IPC: C12N15/86 ,  C12N15/113

CPC classification number: C12N15/86 ,  C12N15/113 ,  C12N2310/141 ,  C12N2310/315 ,  C12N2310/321

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to MeCP2 loss and/or misfunction, including RETT syndrome. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a MeCP2 polypeptide.

公开(公告)号：US20240150396A1

公开(公告)日：2024-05-09

申请号：US18280400

申请日：2022-03-03

Applicant: The Texas A&M University System ,  The Board of Regents of the University of Texas System

Inventor： Thomas D. Meek ,  Linfeng Li ,  Chien-Te Kent Tseng ,  Aleksandra Drelich

IPC: C07K5/078 ,  A61P31/14 ,  A61P33/02

CPC classification number: C07K5/06139 ,  A61P31/14 ,  A61P33/02 ,  A61K38/00

Abstract: Provided herein are pharmaceutical compositions including compounds having Formula (I) in an effective amount to inhibit cysteine protease as well as methods of using thereof.

公开(公告)号：US11969522B2

公开(公告)日：2024-04-30

申请号：US16922355

申请日：2020-07-07

Applicant: The Board of Regents of the University of Texas System ,  Edward Keefer

Inventor： Jonathan Cheng ,  Edward Keefer ,  Srikanth Vasudevan

IPC: A61L27/18 ,  A61K38/18 ,  A61K45/06 ,  A61K31/395 ,  A61K31/5377 ,  C07D257/02

CPC classification number: A61L27/18 ,  A61K38/18 ,  A61K38/185 ,  A61K38/1866 ,  A61K45/06 ,  A61K31/395 ,  A61K31/5377 ,  A61L2430/32 ,  C07D257/02

Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

公开(公告)号：US20240108381A1

公开(公告)日：2024-04-04

申请号：US18376796

申请日：2023-10-04

Applicant: The Board of Regents of the University of Texas System

Inventor： Edward P. Southern

IPC: A61B17/70

CPC classification number: A61B17/7022 ,  A61B17/7014 ,  A61B2017/00862

Abstract: In one embodiment, a spinal tethering system includes multiple bone anchors each configured to be secured to a vertebra of the spine, a tether configured to connect and apply tension to the bone anchors for the purpose of modulating growth of the spine, and a clutch mechanism configured to selectively release the tether to enable adjustment of the tether and, therefore, adjustment of the tension that the tether applies to the bone anchors.

公开(公告)号：US11946065B2

公开(公告)日：2024-04-02

申请号：US17387035

申请日：2021-07-28

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Berge A. Minassian ,  Emrah Gumusgoz

IPC: C12N15/864 ,  C12N7/00 ,  C12N15/11 ,  C12N15/113 ,  C12N15/15 ,  C12N15/86

CPC classification number: C12N15/86 ,  C12N7/00 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.

公开(公告)号：US20240101667A1

公开(公告)日：2024-03-28

申请号：US18255745

申请日：2021-12-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Guojin WU ,  Jaehyup KIM ,  Heyu CHEN ,  Mi DENG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Ryan HUANG

IPC: C07K16/28 ,  A61P35/02 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61P35/02 ,  G01N33/574 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.

公开(公告)号：US20240101637A1

公开(公告)日：2024-03-28

申请号：US18465333

申请日：2023-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  BAYLOR COLLEGE OF MEDICINE

Inventor： John Lee SPUDICH ,  Elena G. GOVORUNOVA ,  Oleg A. SINESHCHEKOV ,  Mingshan XUE

IPC: C07K14/705 ,  A61K48/00 ,  A61P27/02

CPC classification number: C07K14/705 ,  A61K48/0058 ,  A61P27/02

Abstract: Methods and compositions used to identify and characterize novel rhodopsin domains, which are kalium (potassium)-conducting channelrhodopsins. The rhodopsin domain of these kalium (potassium)-conducting channelrhodopsins have been cloned, optimized and expressed in mammalian systems and thus may be used in, among others, optogenetic applications and as therapeutic agents for electrically active cell mediated disorders.

公开(公告)号：US20240059647A1

公开(公告)日：2024-02-22

申请号：US18173413

申请日：2023-02-23

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Kyoji TSUCHIKAMA ,  Yasuaki ANAMI ,  Chisato TSUCHIKAMA ,  Ningyang ZHANG ,  Zhiqiang AN

IPC: C07C247/04 ,  A61K47/68 ,  A61P35/00 ,  A61K31/40 ,  C07D209/20 ,  C07D403/12

CPC classification number: C07C247/04 ,  A61K47/6889 ,  A61P35/00 ,  A61K31/40 ,  C07D209/20 ,  C07D403/12 ,  A61K45/06

Abstract: In one aspect, the present disclosure provides compounds of the formula:




wherein the variables are as defined herein.
In another aspect, the present disclosure provides compounds of the formula:




wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.